Cesano

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Thursday, November 17, 2022
Marketing, COVID-19, EPIX, Doctor of Philosophy, University of Turin, GSK, Clinical Colorectal Cancer, Alessandra, Food, University, Team, Amgen, Knowledge, Patient, MD, Security (finance), Cesano, Food and Drug Administration Amendments Act of 2007, Ridinilazole, Cancer, Self-signed certificate, Biogen, Risk, Panitumumab, Prostate cancer, Quality of life, SMMT, CMO, Coronavirus, Clinical trial, Medical imaging, Pharmaceutical industry

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.
  • Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs, stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • Dr. Cesano currently serves on the board of Puma Biotechnology Inc. (NASDAQ: PBYI), a clinical stage oncology company focused on solid tumors.
  • Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer

Retrieved on: 
Monday, July 15, 2019
Cesano, Drug development, Life sciences, Natural sciences

With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing.

Key Points: 
  • With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing.
  • said David Parkinson, MD, President & Chief Executive Officer of ESSA.
  • Dr. Cesano is an accomplished drug development leader with extensive experience in drug discovery and development.
  • Dr. Cesano received an M.D., a Board Certification in Oncology and a Ph.D. in Tumor Immunology from the University of Turin.